Suppr超能文献

滤泡性淋巴瘤的初始管理策略

Initial management strategies for follicular lymphoma.

作者信息

Chen Qiushi, Ayer Turgay, Nastoupil Loretta J, Seward Miray, Zhang Hongzheng, Sinha Rajni, Flowers Christopher R

机构信息

H Milton Stewart School of Industrial & Systems Engineering , Georgia Institute of Technology, Atlanta, GA 30332, USA.

出版信息

Int J Hematol Oncol. 2012 Oct;1(1):35-45. doi: 10.2217/ijh.12.7.

Abstract

Follicular lymphoma (FL) can vary markedly in its initial presentation, and no single standard approach for its initial management has been adopted. Available options for the initial management of FL include watchful waiting, radiation, single-agent rituximab and combination of rituximab and chemotherapy with strategies segregated for patients who have low and high tumor burden disease based on established criteria. However, marked debate occurs regarding the role of watchful waiting in the modern era for low tumor burden, asymptomatic patients, the optimal timing of rituximab, the selection of chemotherapy regimen to partner with rituximab in high tumor burden patients, and strategies for the management of relapsed disease. We provide an evidence-based discussion on these and other issues regarding the management of FL, and propose a mathematical modeling approach for addressing some of these questions.

摘要

滤泡性淋巴瘤(FL)的初始表现差异显著,目前尚未采用单一的标准初始治疗方法。FL初始治疗的可用选项包括观察等待、放疗、单药利妥昔单抗以及基于既定标准将利妥昔单抗与化疗联合应用于低肿瘤负荷和高肿瘤负荷疾病患者的策略。然而,对于观察等待在现代低肿瘤负荷、无症状患者中的作用、利妥昔单抗的最佳使用时机、高肿瘤负荷患者中与利妥昔单抗联合使用的化疗方案选择以及复发疾病的管理策略等问题,存在激烈的争论。我们对这些以及其他关于FL治疗的问题进行基于证据的讨论,并提出一种数学建模方法来解决其中一些问题。

相似文献

1
Initial management strategies for follicular lymphoma.
Int J Hematol Oncol. 2012 Oct;1(1):35-45. doi: 10.2217/ijh.12.7.
3
Follicular lymphoma: first-line treatment without chemotherapy for follicular lymphoma.
Curr Treat Options Oncol. 2015 Jul;16(7):32. doi: 10.1007/s11864-015-0351-7.
4
Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895. Epub 2016 Jan 5.
5
[Management strategy for follicular lymphoma].
Rinsho Ketsueki. 2017;58(10):2020-2025. doi: 10.11406/rinketsu.58.2020.
6
[Follicular lymphoma: recent advances].
Rinsho Ketsueki. 2018;59(10):2104-2108. doi: 10.11406/rinketsu.59.2104.
7
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
8
Treatment of follicular lymphoma.
J Clin Exp Hematop. 2014;54(1):31-7. doi: 10.3960/jslrt.54.31.
9
Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?
Hematology Am Soc Hematol Educ Program. 2012;2012:433-8. doi: 10.1182/asheducation-2012.1.433.
10
[The current therapeutic landscape for follicular lymphoma].
Rinsho Ketsueki. 2021;62(8):1070-1076. doi: 10.11406/rinketsu.62.1070.

引用本文的文献

2
Oral Lichenoid Reaction: An Uncommon Side Effect of Rituximab.
Case Rep Dent. 2019 Nov 6;2019:3154856. doi: 10.1155/2019/3154856. eCollection 2019.
3
Microsimulation Modeling in Oncology.
JCO Clin Cancer Inform. 2018 Dec;2:1-11. doi: 10.1200/CCI.17.00029.
4
Lichenoid mucosal reaction to rituximab.
Oncologist. 2014 Oct;19(10):e12-3. doi: 10.1634/theoncologist.2014-0169. Epub 2014 Aug 28.

本文引用的文献

2
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States.
Leuk Lymphoma. 2015 May;56(5):1295-302. doi: 10.3109/10428194.2014.953144. Epub 2014 Nov 5.
4
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.
J Clin Oncol. 2012 Sep 20;30(27):3368-75. doi: 10.1200/JCO.2011.40.6546. Epub 2012 Aug 20.
6
Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.
J Clin Oncol. 2011 Oct 20;29(30):3990-8. doi: 10.1200/JCO.2011.34.8508. Epub 2011 Sep 19.
7
Informing sequential clinical decision-making through reinforcement learning: an empirical study.
Mach Learn. 2011 Jul 1;84(1-2):109-136. doi: 10.1007/s10994-010-5229-0.
8
Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors.
Oper Res. 2010 Nov 1;58(6):1577-1591. doi: 10.1287/opre.1100.0877.
10
A decade of progress in lymphoma: advances and continuing challenges.
Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):414-23. doi: 10.3816/CLML.2010.n.086.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验